Reading from the Same Playbook
This article was originally published in RPM Report
Commissioner Hamburg and Rep. Rosa DeLauro draw on siimilar themes--and similar words--in making the case for regulatory science.
You may also be interested in...
FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.